Nuvilex to Attend 2015 Gastrointestinal Cancers Symposium in San Francisco, January 15-17, 2015
January 06 2015 - 9:30AM
InvestorsHub NewsWire
SILVER SPRING, MD -
January 06, 2015 - InvestorsHub NewsWire - Nuvilex, Inc. (OTCQB:
NVLX) today announced that its Chief Executive Officer (CEO),
Kenneth L Waggoner, JD, and its Chief Operating Officer, Gerald W.
Crabtree, Ph.D., will be attending the 2015 Gastrointestinal
Cancers Symposium, “Bridging Cancer Biology to Clinical GI
Oncology,” to be held in the Moscone West Convention Center in San
Francisco, California, January 15-17, 2015.
Nuvilex’s CEO, Kenneth L. Waggoner, stated, “Our attendance at this
pivotal Symposium, which is dedicated to recent advances in the
treatment of cancers of the GI tract, is essential because a
substantial portion of the Symposium will be dedicated to the
treatment of pancreatic cancer and because a significant component
of Nuvilex’s portfolio is devoted to the development of treatments
for this deadly disease and the symptoms associated with it. The
treatments Nuvilex will employ to attack pancreatic cancer are
based on the use of the proprietary Cell-in-a-Box®
cellulose-based live cell encapsulation technology in combination
with low doses of the anticancer prodrug ifosfamide that has been
deemed effective in two previous clinical trials. Our targeted
chemotherapy platform has now shown encouraging results in early
preclinical studies in the U.S. performed by Translational Drug
Development (TD2) that are concerned with the development of
malignant ascites fluid in animals with an abdominal cancer.”
The Gastrointestinal Cancers Symposium is an annual event held in
January in San Francisco and is co-sponsored by the American
Gastroenterological Association, the American Society of Clinical
Oncology, the American Society of Radiation Oncology, the American
Society for Radiation Oncology and the Society of Surgical
Oncology. This Symposium is expected to attract over 3,000
participants from around the world who are experts in the treatment
of cancers of the pancreas, small bowel, colon, rectum,
hepatobiliary tract, esophagus and stomach. At this event, many of
the latest developments in the prevention, screening, diagnosis,
multidisciplinary treatment and translational research of GI
cancers will be presented.
About Nuvilex
Nuvilex is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as Cell-in-a-Box®. This
unique and patented technology will be used as a platform upon
which treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
Nuvilex’s treatment for pancreatic cancer involves low doses of the
well-known anticancer prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or "cancer-killing" form. These capsules are placed as close to the
cancerous tumor as possible to enable the delivery of the highest
levels of the cancer-killing drug at the source of the cancer. This
“targeted chemotherapy” has proven remarkably effective in past
clinical trials. In addition, Nuvilex is working towards improving
the quality of life for patients with advanced pancreatic cancer
and on treatments for other types of solid cancerous tumors.
Nuvilex is also developing treatments for cancer based upon
chemical constituents of marijuana known as cannabinoids. In doing
so, Nuvilex is examining ways to exploit the benefits of
Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of cannabinoids, while minimizing or outright
eliminating the debilitating side effects usually associated with
cancer treatments. This provides Nuvilex the rare opportunity to
develop “green” approaches to fighting deadly cancers, such as
those of the pancreas, brain and breast, which affect hundreds of
thousands of individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking statements regarding
Nuvilex and its future events and results that involve inherent
risks and uncertainties. The words "anticipate," "believe,"
"estimate," "expect," "intend," "plan" and similar expressions, as
they relate to Nuvilex or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of Nuvilex, could cause actual results to differ
materially from those set forth in the forward-looking statements.
They include Nuvilex's ability to continue as a going concern,
delays or unsuccessful results in clinical trials or flaws or
defects regarding its product candidates, changes in relevant
legislation or regulatory requirements, uncertainty of protection
of Nuvilex's intellectual property and Nuvilex's continued ability
to raise capital. Nuvilex does not assume any obligation to update
any of these forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting
Investor Relations.
Investor Relations Contacts:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com